Accueil   Agenda - News   Toutes les news Signia Therapeutics successfully achieved the first phase of the EU H2020 SME INSTRUMENT FUNDING

Signia Therapeutics successfully achieved the first phase of the EU H2020 SME INSTRUMENT FUNDING

 

 

Signia Therapeutics is very prood to announce that it's successfully achieved the first phase of the EU H2020 SME INSTRUMENT FUNDING for its innovative drug discovery Platform allowing rapid identification and validation of antimicrobial applications in available pharmaceutical resources and drugs open for repurposing.

 

This recognition completes the Seal of Excellence awarded by the European Commission, as the institution managing the H2020 EU Framework Program for Research and Innovation

 

 

https://ec.europa.eu/programmes/horizon2020/en/h2020-section/sme-instrument

 

 

 

 

En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies pour vous proposer des services et offres adaptés à vos centres d'intérêt. En savoir plus... Fermer